@acammarota.bsky.social presenting her work on clinical predictors and molecular architecture of #TLS in #CCA 🔬at @easlnews.bsky.social #LiverCancerSummit in Edinburgh. Great job! 👏🏻👏🏻👏🏻 #AnaLleo #HumanitasUniversity #Humanitas

On #ClinicalTrialsDay, meet the next generation driving #CancerResearch forward. 👩🏻‍⚕️ In this video, Ioannis, Jens, and Antonella share what it means to be part of the EORTC Early Career Investigator community. Learn more: www.eortc.org/blog/2025/05... ▶️ youtu.be/cjPQDCxrZbI

Meet the EORTC Early Career Investigators

YouTube video by EORTC

youtu.be

Please have a look at our comment on #ICI and #TKI for unresectable #HCC published in @thelancetoncol.bsky.social @acammarota.bsky.social

The Lancet Oncology@thelancetoncol.bsky.social · last yr.

Online: Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable #HepatocellularCarcinoma (APOLLO): a randomised, controlled, phase 3 trial bit.ly/4m9pBEZ

"Science is a career for anyone curious enough to ask why, and stubborn enough to keep on asking." Yes, love this

Adrian Liston@labliston.bsky.social · 2y ago

"Becoming a #Scientist: The Graphic Novel" goes through the stories of my amazing lab members. Every one has a unique pathway, overcoming personal challenges. They are an inspirational #team! www.thegreatbritishbookshop.co.uk/products/bec...

Only a subset of patients respond to immunotherapy Why? Which ones? We conducted an unbiased analysis of response biomarkers and found that hundreds of possible biomarkers collapse into five latent, orthogonal factors that underlie immunotherapy response. www.nature.com/articles/s41...

Nice work from my (ex 😥) fellow @acammarota.bsky.social 👏👏 Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show: ✅Strong link between PD-L1 and pathological response. ✖️ Less so OS .. www.esmogastro.org/article/S294... Looking forward to MATTERHORN next year!

PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials

Perioperative chemoimmunotherapy [i.e. chemotherapy plus immune checkpoint inhibitor (ICI) (ChT–ICI)] is an investigational treatment for operable gastroesophageal adenocarcinoma (GEA) with unclear ou...

esmogastro.org